Cellectis S.A. (ALCLS.PA)
EUR 1.45
(4.01%)
EUR 1.45
(4.01%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 71.39 Million USD | 2.15% |
| 2022 | 69.88 Million USD | -23.67% |
| 2021 | 91.55 Million USD | -12.47% |
| 2020 | 104.6 Million USD | 124.75% |
| 2019 | 46.54 Million USD | 4471.71% |
| 2018 | 1.01 Million USD | 7730.77% |
| 2017 | 13 Thousand USD | -55.85% |
| 2016 | 29.44 Thousand USD | -59.19% |
| 2015 | 72.15 Thousand USD | -97.9% |
| 2014 | 3.43 Million USD | -26.32% |
| 2013 | 4.66 Million USD | 6.69% |
| 2012 | 4.36 Million USD | -93.53% |
| 2011 | 67.51 Million USD | 6174.59% |
| 2010 | 1.07 Million USD | -58.87% |
| 2009 | 2.61 Million USD | 44.12% |
| 2008 | 1.81 Million USD | 0.0% |
| 2007 | - USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 77.87 Million USD | -1.65% |
| 2024 Q1 | 80.76 Million USD | 41.25% |
| 2023 Q4 | 71.39 Million USD | 0.82% |
| 2023 Q2 | 86.42 Million USD | 42.0% |
| 2023 FY | 71.39 Million USD | 2.15% |
| 2023 Q3 | 70.81 Million USD | -18.07% |
| 2023 Q1 | 60.86 Million USD | -12.91% |
| 2022 Q3 | 78.29 Million USD | -3.37% |
| 2022 Q4 | 69.88 Million USD | -10.73% |
| 2022 FY | 69.88 Million USD | -23.67% |
| 2022 Q2 | 81.02 Million USD | -6.71% |
| 2022 Q1 | 86.85 Million USD | -5.14% |
| 2021 Q3 | 95.21 Million USD | -2.75% |
| 2021 Q4 | 91.55 Million USD | -3.84% |
| 2021 FY | 91.55 Million USD | -12.47% |
| 2021 Q1 | 96.71 Million USD | -7.53% |
| 2021 Q2 | 97.9 Million USD | 1.22% |
| 2020 Q3 | 98.83 Million USD | 38.22% |
| 2020 FY | 104.6 Million USD | 124.75% |
| 2020 Q4 | 104.6 Million USD | 5.84% |
| 2020 Q1 | 48.69 Million USD | 4.64% |
| 2020 Q2 | 71.5 Million USD | 46.83% |
| 2019 Q2 | 45.71 Million USD | 51.04% |
| 2019 Q4 | 46.54 Million USD | 4.66% |
| 2019 FY | 46.54 Million USD | 4471.71% |
| 2019 Q3 | 44.46 Million USD | -2.72% |
| 2019 Q1 | 30.26 Million USD | 2872.79% |
| 2018 Q1 | 265 Thousand USD | 1938.46% |
| 2018 Q4 | 1.01 Million USD | 387.08% |
| 2018 Q3 | 209 Thousand USD | -9.52% |
| 2018 Q2 | 231 Thousand USD | -12.83% |
| 2018 FY | 1.01 Million USD | 7730.77% |
| 2017 Q3 | 17 Thousand USD | -17.44% |
| 2017 Q2 | 20.59 Thousand USD | -8.24% |
| 2017 Q1 | 22.44 Thousand USD | -23.8% |
| 2017 FY | 13 Thousand USD | -55.85% |
| 2017 Q4 | 13 Thousand USD | -23.53% |
| 2016 FY | 29.44 Thousand USD | -59.19% |
| 2016 Q4 | 29.44 Thousand USD | -29.06% |
| 2016 Q2 | 42.26 Thousand USD | -32.19% |
| 2016 Q3 | 41.5 Thousand USD | -1.8% |
| 2016 Q1 | 62.33 Thousand USD | -13.62% |
| 2015 Q4 | 72.15 Thousand USD | -13.34% |
| 2015 FY | 72.15 Thousand USD | -97.9% |
| 2015 Q3 | 83.26 Thousand USD | -19.31% |
| 2015 Q2 | 103.18 Thousand USD | -81.81% |
| 2015 Q1 | 567.22 Thousand USD | -83.48% |
| 2014 Q1 | 3.81 Million USD | -18.1% |
| 2014 FY | 3.43 Million USD | -26.32% |
| 2014 Q4 | 3.43 Million USD | -3.65% |
| 2014 Q3 | 3.56 Million USD | -5.69% |
| 2014 Q2 | 3.77 Million USD | -0.99% |
| 2013 Q3 | 4.56 Million USD | -0.46% |
| 2013 Q4 | 4.66 Million USD | 2.03% |
| 2013 FY | 4.66 Million USD | 6.69% |
| 2013 Q2 | 4.58 Million USD | 1.46% |
| 2013 Q1 | 4.52 Million USD | 3.54% |
| 2012 FY | 4.36 Million USD | -93.53% |
| 2012 Q3 | 3.26 Million USD | -16.35% |
| 2012 Q4 | 4.36 Million USD | 33.75% |
| 2012 Q2 | 3.9 Million USD | 0.0% |
| 2011 Q4 | 67.51 Million USD | 0.0% |
| 2011 FY | 67.51 Million USD | 6174.59% |
| 2010 Q4 | 1.07 Million USD | 0.0% |
| 2010 FY | 1.07 Million USD | -58.87% |
| 2010 Q2 | - USD | 0.0% |
| 2009 Q4 | 2.61 Million USD | 0.0% |
| 2009 Q2 | - USD | 0.0% |
| 2009 FY | 2.61 Million USD | 44.12% |
| 2008 FY | 1.81 Million USD | 0.0% |
| 2008 Q4 | 1.81 Million USD | 0.0% |
| 2007 FY | - USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | 1.1 Million EUR | -6384.287% |
| ABIVAX Société Anonyme | 44.69 Million EUR | -59.724% |
| Adocia SA | 4.54 Million EUR | -1472.511% |
| Aelis Farma SA | 2.04 Million EUR | -3385.938% |
| Biophytis S.A. | 3.11 Million EUR | -2194.825% |
| Advicenne S.A. | 15.89 Million EUR | -349.119% |
| genOway Société anonyme | 5.51 Million EUR | -1193.497% |
| IntegraGen SA | 642.28 Thousand EUR | -11015.401% |
| Medesis Pharma S.A. | 1.2 Million EUR | -5849.333% |
| Neovacs S.A. | 650 Thousand EUR | -10883.385% |
| NFL Biosciences SA | 39.2 Thousand EUR | -182008.512% |
| Plant Advanced Technologies SA | 4.35 Million EUR | -1538.743% |
| Quantum Genomics Société Anonyme | 1.96 Million EUR | -3541.838% |
| Sensorion SA | 1.24 Million EUR | -5653.193% |
| Theranexus Société Anonyme | 2.46 Million EUR | -2801.267% |
| TME Pharma N.V. | - EUR | -Infinity% |
| Valbiotis SA | 3.89 Million EUR | -1731.503% |
| TheraVet SA | 1 Million EUR | -7034.926% |
| Valerio Therapeutics Société anonyme | 6.9 Million EUR | -933.768% |
| DBV Technologies S.A. | 4.52 Million USD | -1477.375% |
| Genfit S.A. | 62.25 Million EUR | -14.68% |
| GeNeuro SA | 6.49 Million EUR | -999.641% |
| Innate Pharma S.A. | 30.6 Million EUR | -133.254% |
| Inventiva S.A. | 25.61 Million EUR | -178.701% |
| MaaT Pharma SA | 5.42 Million EUR | -1215.982% |
| MedinCell S.A. | 52.8 Million EUR | -35.212% |
| Nanobiotix S.A. | 41.66 Million EUR | -71.368% |
| OSE Immunotherapeutics SA | 35.5 Million EUR | -101.059% |
| Poxel S.A. | 40.14 Million EUR | -77.844% |
| GenSight Biologics S.A. | 1.04 Million EUR | -6712.214% |
| Transgene SA | 17 Thousand EUR | -419852.941% |
| Valneva SE | 132.76 Million EUR | 46.228% |